127 related articles for article (PubMed ID: 34182567)
1. Comparing the Effects of Febuxostat and Allopurinol in an Animal Model of Metabolic Syndrome.
Nadwa EH; Morcos GNB; Salama NM; Shafik AN
Pharmacology; 2021; 106(9-10):564-572. PubMed ID: 34182567
[TBL] [Abstract][Full Text] [Related]
2. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Nishikawa T; Nagata N; Shimakami T; Shirakura T; Matsui C; Ni Y; Zhuge F; Xu L; Chen G; Nagashimada M; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S; Ota T
Sci Rep; 2020 Jan; 10(1):815. PubMed ID: 31965018
[TBL] [Abstract][Full Text] [Related]
3. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
Kohagura K; Tana T; Higa A; Yamazato M; Ishida A; Nagahama K; Sakima A; Iseki K; Ohya Y
Hypertens Res; 2016 Aug; 39(8):593-7. PubMed ID: 27075830
[TBL] [Abstract][Full Text] [Related]
4. Xanthine oxidase inhibitor febuxostat reduces atrial fibrillation susceptibility by inhibition of oxidized CaMKII in Dahl salt-sensitive rats.
Xu D; Murakoshi N; Tajiri K; Duo F; Okabe Y; Murakata Y; Yuan Z; Li S; Aonuma K; Song Z; Shimoda Y; Mori H; Sato A; Nogami A; Aonuma K; Ieda M
Clin Sci (Lond); 2021 Oct; 135(20):2409-2422. PubMed ID: 34386810
[TBL] [Abstract][Full Text] [Related]
5. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
6. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin and xanthine oxidase inhibitors improve insulin resistance and modulate renal glucose and urate transport in metabolic syndrome.
Ng HY; Leung FF; Kuo WH; Lee WC; Lee CT
Clin Exp Pharmacol Physiol; 2021 Dec; 48(12):1603-1612. PubMed ID: 34407232
[TBL] [Abstract][Full Text] [Related]
8. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
9. Febuxostat improves the local and remote organ changes induced by intestinal ischemia/reperfusion in rats.
Shafik AN
Dig Dis Sci; 2013 Mar; 58(3):650-9. PubMed ID: 23010742
[TBL] [Abstract][Full Text] [Related]
10. Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
Szasz T; Davis RP; Garver HS; Burnett RJ; Fink GD; Watts SW
PLoS One; 2013; 8(2):e56046. PubMed ID: 23393607
[TBL] [Abstract][Full Text] [Related]
11. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
12. Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.
Omizo H; Tamura Y; Morimoto C; Ueno M; Hayama Y; Kuribayashi-Okuma E; Uchida S; Shibata S
Sci Rep; 2020 Jun; 10(1):9326. PubMed ID: 32518351
[TBL] [Abstract][Full Text] [Related]
13. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
14. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome.
Sánchez-Lozada LG; Tapia E; Bautista-García P; Soto V; Avila-Casado C; Vega-Campos IP; Nakagawa T; Zhao L; Franco M; Johnson RJ
Am J Physiol Renal Physiol; 2008 Apr; 294(4):F710-8. PubMed ID: 18216151
[TBL] [Abstract][Full Text] [Related]
15. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
[TBL] [Abstract][Full Text] [Related]
16. Effects of allopurinol, a xanthine oxidase inhibitor, on renal injury in hypercholesterolemia-induced hypertensive rats.
Minami M; Ishiyama A; Takagi M; Omata M; Atarashi K
Blood Press; 2005; 14(2):120-5. PubMed ID: 16036490
[TBL] [Abstract][Full Text] [Related]
17. Role of allopurinol and febuxostat in the amelioration of dextran-induced colitis in rats.
El-Mahdy NA; Saleh DA; Amer MS; Abu-Risha SE
Eur J Pharm Sci; 2020 Jan; 141():105116. PubMed ID: 31654756
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones.
Goldfarb DS; MacDonald PA; Gunawardhana L; Chefo S; McLean L
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1960-7. PubMed ID: 23929928
[TBL] [Abstract][Full Text] [Related]
19. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
[TBL] [Abstract][Full Text] [Related]
20. Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.
Šmelcerović A; Tomović K; Šmelcerović Ž; Petronijević Ž; Kocić G; Tomašič T; Jakopin Ž; Anderluh M
Eur J Med Chem; 2017 Jul; 135():491-516. PubMed ID: 28478180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]